Ibrutinib heart risks under the microscope: can we predict them?
NCT ID NCT05939752
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to understand why some people taking the cancer drug ibrutinib develop heart issues like atrial fibrillation (irregular heartbeat) and high blood pressure. Researchers planned to follow 8 patients with blood cancers, using heart tests and blood markers to try to predict who was at risk. The study was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
8 people
The number who actually took part.
- Started
-
Dec 2023
- Finished
-
Aug 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Eligible patients will be identified by a doctor working in the hematology department of Dijon University Hospital during his or her regular medical check-up.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with an indication for ibrutinib treatment for hematologic reasons * Patients aged 18 and over * Patients who have given their free, written and informed consent to this study after being informed (or by the patient's representative if the patient is unable to express his or her consent). Exclusion Criteria: * Person not affiliated to national health insurance * Patient under legal protection (curatorship, guardianship) * Patient subject to a safeguard of justice measure * Pregnant, parturient or breast-feeding women * Previous treatment with ibrutinib * Follow-up planned in another center * History of atrial fibrillation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic lymphocytic leukemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chu Dijon Bourgogne
Dijon, 21000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Off-the-Shelf Gene-Edited immune cells tested against Hard-to-Treat lymphoma
- Triple drug combo targets mantle cell lymphoma
- New drug joins standard chemotherapy in fight against B-Cell lymphoma
- Two-Drug combo aims to push CLL into deep remission
- Can a new BTK inhibitor outsmart resistance in CLL?
- Which lymphoma drug combo works best? a new study aims to find out